Kulika Weizman is a principal at Creative Ventures, investing in early-stage deeptech companies solving humanity’s most critical crises: rising healthcare costs, climate change, and labor shortages. Kulika leverages her scientific expertise and operational experience as a synthetic biology company’s founding CEO to lead new investments, formulate investment theses, and support existing portfolio companies to success. Kulika holds a PhD in Microbiology from University of California, Berkeley, BS in Economics from the Wharton School, and BS in Chemical and Biomolecular Engineering from the University of Pennsylvania.

© 2024 BioFutureTM. All Rights Reserved

Produced by